-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

321. Blood Coagulation and Fibrinolytic Factors: Poster III Clinically Relevant Abstract

Program: Oral and Poster Abstracts
Type: Poster
Hematology Disease Topics & Pathways:
antibodies, Biological, Bleeding Disorders, Coronaviruses, Hemophilia, Bleeding and Clotting, Diseases, Hemostasis, Therapies, Pediatric, Biological Processes, Thrombosis, gene therapy, Platelet Disorders, Technology and Procedures, Protein Disorders, Study Population, Clinically relevant, Quality Improvement , VWD, molecular interactions, pathways, proteomics
Monday, December 7, 2020: 7:00 AM-3:30 PM

Yi Liu, MS1*, Wenpeng Cao, PhD2*, Wenjing Cao, MD, PhD3*, X. Long Zheng, MD, PhD4* and Xiaohui Zhang, PhD5

1Department of Bioengineering, Lehigh University, Bethlehem, PA
2Departments of Bioengineering, Lehigh University, Bethlehem, PA
3Department of Pathology and Laboratory Medicine,, The University of Kansas Medical Center,, Kansas City, KS
4University of Kansas Medical Center, Kansas City, KS
5Department of Bioengineering, Department of Mechanical Engineering and Mechanics, Lehigh University, Bethlehem, PA

Haarin Chun, PhD*, John R Pettersson, PhD*, Svetlana A Shestopal, PhD*, Wells W Wu, PhD*, Ekaterina S Marakasova*, Philip Olivares, PhD*, Stepan S Surov, PhD*, Mikhail V Ovanesov, PhD*, Rong-Fong Shen, PhD*, Timothy K Lee, PhD* and Andrey G Sarafanov, PhD*

Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD

Brian Lauritzen1*, Mads Bjelke2*, Marie Rossen2*, Mikala Skydsgaard2*, Marianne Kjalke, PhD2*, Olle Björkdahl2* and Stine L Kjellev, PhD, DVM3*

1Novonordisk A/S, Maaloev, Denmark
2Novo Nordisk A/S, Maaloev, Denmark
3Global Drug Discovery, Novo Nordisk A/S, Maaloev, Denmark, Denmark

Ri J. Liesner1* and Ellis J. Neufeld2

1Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children NHS Foundation Trust, London, ENG, United Kingdom
2St. Jude Children's Research Hospital, Memphis, TN

Amy W Strilchuk1, Christian Kastrup1*, Joseph S. Palumbo, MD2 and Pieter Cullis, PhD1*

1University of British Columbia, Vancouver, BC, Canada
2Children's Hospital Med. Ctr., Cincinnati, OH

Meera Sridharan, MD, PhD1, Aneel A. Ashrani, MD, MS1, Dong Chen, M.D., Ph.D.2, Nahla M. Heikal, MD2*, Ariela L. Marshall, MD1 and Rajiv K. Pruthi, M.B.B.S1,3

1Division of Hematology, Mayo Clinic, Rochester, MN
2Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
3Division of Hematopathology, Special Coagulation Laboratory, Mayo Clinic, Rochester, MN

Megan C. Brown, MD and Gary Woods, MD

Department of Pediatrics, Emory University School of Medicine, Children's Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center, Atlanta, GA

*signifies non-member of ASH